NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.397) was uploaded to the NHS England Website on Thursday 14, May 2026.
The following changes have been introduced:
Durvalumab with chemotherapy (DUR9)
For neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Niraparib (NIR3)
Niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who HAVE deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation [NICE TA673] where the following criteria have been met There is a separate form NIR4 for use of niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy and who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation
Moved into routine commissioning - section B of list
Talazoparib plus enzalutamide (TAL2)
For the treatment of metastatic hormone- relapsed (castrate-resistant) prostate cancer in patients who are treatment naïve to androgen receptor inhibitors and in whom chemotherapy is not yet clinically indicated or appropriate where the following criteria have been met
Moved into routine commissioning - section B of list
Cetuximab in combination with fluoropyrimidine-based chemotherapy (CET5)
For chemotherapy-naive metastatic or locally advanced and inoperable colorectal cancer where all the following criteria are met:
Added to section B, merging forms CET1, CET2 and CET4
Panitumumab in combination with fluoropyrimidine-based chemotherapy (PAN4)
For chemotherapy-naive metastatic or locally advanced and inoperable colorectal cancer where the following criteria are met: Panobinostat for treating multiple
Added to section B, merging forms PAN1, PAN2 and PAN3